Drug Profile


Alternative Names: Progenipoietin-G; ProGP-G

Latest Information Update: 30 Mar 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacia Corporation
  • Class Antineoplastics; Colony-stimulating factors; Recombinant proteins
  • Mechanism of Action Immunostimulants; Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Myelosuppression

Most Recent Events

  • 30 Mar 2001 Discontinued-I for Cancer in USA (Unknown route)
  • 30 Mar 2001 Discontinued-I for Myelosuppression in USA (Unknown route)
  • 26 Jul 2000 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top